Published in Osteoporos Int on November 04, 2010
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res (2013) 1.44
Short- and long-term mortality in males and females with fragility hip fracture in Norway. A population-based study. Clin Interv Aging (2013) 1.14
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
The effect of treatments for osteoporosis on mortality. Osteoporos Int (2012) 0.87
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int (2012) 0.87
Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions. Osteoporos Int (2011) 0.85
Predictors of short- and long-term mortality in males and females with hip fracture - a prospective observational cohort study. PLoS One (2013) 0.85
Ankle fractures have features of an osteoporotic fracture. Osteoporos Int (2013) 0.83
Epidemiology of osteoporotic hip fractures in Western Romania. Int Orthop (2014) 0.83
Osteoporosis in the community: Sensitivity of self-reported estimates and medication use of those diagnosed with the condition. Bone Joint Res (2012) 0.82
Osteoporosis screening and treatment among veterans with recent fracture after implementation of an electronic consult service. Calcif Tissue Int (2014) 0.81
Medical management in the acute hip fracture patient: a comprehensive review for the internist. Ochsner J (2012) 0.79
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf (2011) 0.79
Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int (2015) 0.79
Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis. Pak J Med Sci (2016) 0.78
Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int (2012) 0.77
Influence of Early Bisphosphonate Administration for Fracture Healing in Patients with Osteoporotic Proximal Humerus Fractures. Clin Orthop Surg (2016) 0.76
For the first fracture to be the last. Rev Bras Ortop (2016) 0.75
Gender Disparities in Osteoporosis. J Clin Med Res (2017) 0.75
Geographic scope and accessibility of a centralized, electronic consult program for patients with recent fracture. Rural Remote Health (2016) 0.75
Improving care after hip fracture: the fracture? Think osteoporosis (FTOP) program. BMC Geriatr (2013) 0.75
Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int (2017) 0.75
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). J Bone Miner Res (2017) 0.75
Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
The RAND 36-Item Health Survey 1.0. Health Econ (1993) 10.05
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA (2009) 5.60
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf (2007) 3.66
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med (2003) 2.19
Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc (2002) 1.97
Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med (2008) 1.85
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
Channeling bias in the interpretation of drug effects. Stat Med (1991) 1.65
Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med (2007) 1.63
Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc (2004) 1.45
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int (2003) 1.10
Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med (2009) 1.08
Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res (2010) 0.99
Factors associated with a second hip fracture: a systematic review. Clin Rehabil (2007) 0.96
Post-fracture prescribed calcium and vitamin D supplements alone or, in females, with concomitant anti-osteoporotic drugs is associated with lower mortality in elderly hip fracture patients: a prospective analysis. Drugs Aging (2009) 0.95
Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res (2009) 0.90
Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: additional results from a randomized trial. Arthritis Rheum (2009) 0.84
Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches. Open Med (2010) 0.78
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet (2008) 2.30
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Ankylosing spondylitis--at the interface of bone and cartilage. J Rheumatol (2000) 1.90
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. J Rheumatol (1995) 1.79
Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy. Diabet Med (2006) 1.63
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Transient cough-induced blindness in temporal arteritis. Neurology (2006) 1.41
Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med (2005) 1.35
25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int (2010) 1.34
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab (2009) 1.32
Use of walk-in clinics by rural and urban patients. Can Fam Physician (2000) 1.30
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
Relation of family physician or specialist care to obstetric interventions and outcomes in patients at low risk: a western Canadian cohort study. CMAJ (1989) 1.26
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int (2010) 1.24
Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int (2009) 1.20
The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev (2013) 1.17
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int (2004) 1.15
Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis (2011) 1.15
Underreporting of vertebral fractures on routine chest radiography. AJR Am J Roentgenol (2004) 1.14
Differences in ankle joint complex range of motion as a function of age. Foot Ankle (1993) 1.14
Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int (2006) 1.12
Ankylosing spondylitis in west Africans--evidence for a non-HLA-B*27 protective effect. Ann Rheum Dis (1997) 1.10
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone (2010) 1.07
Do radiographic indices of distal radius fracture reduction predict outcomes in older adults receiving conservative treatment? Clin Radiol (2007) 1.06
Increased continuity of care associated with decreased hospital care and emergency department visits for patients with asthma. Dis Manag (2006) 1.06
Functional, long-term cultures of human term trophoblasts purified by column-elimination of CD9 expressing cells. Placenta (1994) 1.03
Women with previous fragility fractures can be classified based on bone microarchitecture and finite element analysis measured with HR-pQCT. Osteoporos Int (2012) 1.03
Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum (2000) 1.01
The effect of specialist care within the first year on subsequent outcomes in 24,232 adults with new-onset diabetes mellitus: population-based cohort study. Qual Saf Health Care (2007) 0.99
Ossification of the posterior longitudinal ligament in three geographically and genetically different populations of ankylosing spondylitis and other spondyloarthropathies. Ann Rheum Dis (1998) 0.98
Autosomal dominant hypoparathyroidism with intracranial calcification outside the basal ganglia. Am J Med Genet (1989) 0.98
Direct release of parathyroid hormone fragments from functioning bovine parathyroid glands in vitro. J Clin Invest (1978) 0.96
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin (2004) 0.95
Reduced expression of a human V beta 6.1 T-cell receptor allele. Proc Natl Acad Sci U S A (1993) 0.95
Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int (2010) 0.94
Demonstration of functional cytokine-placental interactions: CSF-1 and GM-CSF stimulate human cytotrophoblast differentiation and peptide hormone secretion. Exp Cell Res (1994) 0.94
Mechanical loading regime and its relationship to bone mineral density in children. Med Sci Sports Exerc (1993) 0.94
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. Trials (2008) 0.93
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93
High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int (2011) 0.92
Evidence for reduced Th1 function in normal pregnancy: a hypothesis for the remission of rheumatoid arthritis. J Rheumatol (1997) 0.92
Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Clin Microbiol Infect (2012) 0.91
In vitro perifusion for the study of parathyroid hormone secretion: effects of extracellular calcium concentration and beta-adrenergic regulation on bovine parathyroid hormone secretion in vitro. Calcif Tissue Int (1980) 0.90
Institutionalization following incident non-traumatic fractures in community-dwelling men and women. Osteoporos Int (2011) 0.90
Cell culture models of human trophoblast: primary culture of trophoblast--a workshop report. Placenta (2001) 0.90
Polymorphism in the MHC-encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly. J Rheumatol (2001) 0.89
Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Am J Nephrol (1999) 0.89
Obesity and outcomes in patients hospitalized with pneumonia. Clin Microbiol Infect (2012) 0.89
Preparation and functional characterization of villous cytotrophoblasts free of syncytial fragments. Placenta (2002) 0.88
Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups. Osteoporos Int (2011) 0.88
Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture? Osteoporos Int (2014) 0.88
Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial. Osteoporos Int (2011) 0.88
Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthritis Cartilage (2012) 0.87
Changing osteocalcin concentrations during pregnancy and lactation: implications for maternal mineral metabolism. J Clin Endocrinol Metab (1987) 0.87
Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis (2010) 0.87
Temporal trends in the incidence of osteoporotic fractures. Curr Osteoporos Rep (2013) 0.85
Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions. Osteoporos Int (2011) 0.85
Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. Eur Psychiatry (2010) 0.85
An automaton analysis approach to the study of neural nets. Comput Biomed Res (1967) 0.85
Novel genes and transcription factors in placental development--a workshop report. Placenta (2000) 0.84
Gene regulation of neurokinin B and its receptor NK3 in late pregnancy and pre-eclampsia. Mol Hum Reprod (2006) 0.84
Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial. Diabet Med (2012) 0.84
Dysglycaemia and 90 day and 1 year risks of death or readmission in patients hospitalised for community-acquired pneumonia. Diabetologia (2009) 0.84
Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J Rheumatol (1996) 0.83
Bisphosphonates--targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol (2002) 0.83
Recurrent pneumonia: a review with focus on clinical epidemiology and modifiable risk factors in elderly patients. Drugs Aging (2015) 0.83
Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J Orthop Res (2004) 0.83
EGF promotes development of a differentiated trophoblast phenotype having c-myc and junB proto-oncogene activation. Placenta (1999) 0.83
PL48: a novel gene associated with cytotrophoblast and lineage-specific HL-60 cell differentiation. Gene (1997) 0.83
Retracted Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 0.83
Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int (2010) 0.83
Association between MICA gene A4 allele and acute anterior uveitis in white patients with and without HLA-B27. Am J Ophthalmol (1998) 0.82
Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2005) 0.82
Familial benign hypercalcaemia: hypercalciuria and hypocalciuria in affected members of a small kindred. Clin Endocrinol (Oxf) (1990) 0.82
HLA-DP/DR interaction in children with juvenile rheumatoid arthritis. Immunogenetics (1990) 0.82